Kaleido Biosciences to Present During the Goldman Sachs 41st Annual Global Healthcare Conference

Rhea-AI Summary

Kaleido Biosciences, a clinical-stage healthcare company focused on the microbiome, announced that CEO Alison Lawton will speak at the Goldman Sachs 41st Annual Global Healthcare Conference on June 11, 2020, at 11:20 a.m. ET. Interested parties can access a live webcast through the Investors & Media section on Kaleido's website. The event will also have an archived replay available for 90 days. Kaleido is advancing its pipeline of Microbiome Metabolic Therapies, targeting diseases with significant unmet needs.

LEXINGTON, Mass., June 04, 2020 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven approach to targeting the microbiome to treat disease and improve human health, today announced that Alison Lawton, President and Chief Executive Officer, will participate in a fireside chat during the virtual Goldman Sachs 41^st Annual Global Healthcare Conference on Thursday, June 11, 2020 at 11:20 a.m. ET.

A live webcast will be available in the Investors & Media section of Kaleido’s website at https://investors.kaleido.com/events-presentations. An archived replay will be accessible for 90 days following the event.

About Kaleido Biosciences

Kaleido Biosciences is a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the microbiome to treat disease and improve human health. The Company has built a proprietary product platform to enable the rapid and cost-efficient discovery and development of novel Microbiome Metabolic Therapies (MMT™). MMTs are designed to modulate the metabolic output and profile of the microbiome by driving the function and distribution of the gut’s existing microbes. Kaleido is advancing a broad pipeline of MMT candidates with the potential to address a variety of diseases and conditions with significant unmet patient needs. To learn more, visit https://kaleido.com/.

Contacts

Kaleido Biosciences
William Duke, Jr.
Chief Financial Officer
617-890-5772
william.duke@kaleido.com

Investors

Lee M. Stern
Solebury Trout
646-378-2922
lstern@soleburytrout.com

FAQ

When will Kaleido Biosciences CEO Alison Lawton speak at the Goldman Sachs conference?

Alison Lawton will participate in the fireside chat on June 11, 2020, at 11:20 a.m. ET.

How can I watch the Kaleido Biosciences conference presentation?

You can view the live webcast on Kaleido's website in the Investors & Media section.

What is the focus of Kaleido Biosciences?

Kaleido Biosciences focuses on targeting the microbiome to develop therapies for various diseases.

What are Microbiome Metabolic Therapies?

Microbiome Metabolic Therapies (MMTs) are designed to modulate the microbiome's metabolic output and address unmet patient needs.

Where can I find more information about Kaleido Biosciences?

Additional information can be found on their official website at kaleido.com.